Fluid, analgesic and nutritional management

01Purpose and principlesWhat the treatment does and how it fits into care.

Supportive treatment is active clinical work: each intervention should address a defined problem, have a measurable goal and be reviewed against benefit and harm. Vomiting, reduced intake and inflammatory fluid redistribution can reduce effective circulating volume. Excess fluid can worsen tissue oedema and respiratory function. The objective is therefore adequate perfusion without overload, not the largest feasible infusion volume or a fixed balance target for every patient.

Analgesia and nutrition interact with recovery. Uncontrolled pain impairs breathing, movement and intake, while sedating medicines can obscure deterioration and impair ventilation. Early feasible oral or enteral nutrition avoids unnecessary starvation and supports patients who cannot eat enough. A useful daily plan states what the patient has actually received, whether pain and intake have improved, and how intravenous treatments will be reduced as the clinical situation changes.

Key points

Use lactated Ringer’s for assessed fluid need, usually a moderate approach with repeated perfusion and overload checks; do not prescribe aggressive hydration to prevent necrosis.
An early adult trial example is 1.5 mL/kg/hour, with a 10 mL/kg bolus over two hours only for hypovolaemia; shock and major cardiorenal disease need an individual plan.
Provide prompt analgesia using the selected product’s safety limits. If moderate or severe disease prevents adequate oral intake, start enteral nutrition within 72 hours of presentation; use parenteral nutrition when enteral feeding fails or is contraindicated.
Start oral food when feasible rather than waiting for enzyme normalisation; persistent vomiting or intolerance requires reassessment and another nutritional route.
In moderately severe or severe disease, start enteral nutrition within 72 hours of presentation; nasogastric feeding is acceptable when the gut can be used.
Use parenteral nutrition when enteral feeding is contraindicated, fails or cannot meet needs after assessment; pain alone is not a reason to rest a usable bowel.

02Indications, selection and cautionsWho may benefit, who needs urgent treatment and important alternatives.

Evidence of fluid need

Assess thirst, dry mucosa, vomiting, intake, pulse, blood pressure, peripheral perfusion and urine output together with renal and haematocrit trends. Hypovolaemia can exist before profound hypotension develops. An isolated raised urea or low urine output is insufficient to decide the next volume without examining the patient and checking the response to fluid already given.

Evidence of fluid intoleranceRed flag

Look for new breathlessness, crackles, peripheral oedema, raised venous pressure and a rising oxygen requirement, and interpret the cumulative balance. Overload and inflammatory lung injury can coexist. Slow or stop an infusion when overload is suspected while obtaining urgent assessment; a concurrent low urine output does not automatically justify continuing the same prescription.

Pain and opioid suitability

Record a pain score, functional effect and the response to each analgesic intervention. Review alertness, breathing, blood pressure, bowel function, renal and hepatic status, other sedatives and opioid exposure. PCA requires a patient who understands and can operate the system, a trained team and monitoring. Severe pain does not make every morphine formulation suitable for pancreatitis. The 2026 European pain guidance advises caution with PCA because pancreatitis-specific evidence is sparse; it is a selected method, not a proven superior default.

Feeding tolerance and nutritional risk

Establish recent weight loss, usual intake, vomiting, abdominal distension and the amount actually eaten. Patients who can eat need not progress through a mandatory clear-fluid ladder. Persistent intolerance prompts assessment for ileus, obstruction or other complications and a dietetic plan; malnutrition and refeeding risk can change how support is introduced and monitored.

Red flags requiring action

Breathlessness, new crackles or increasing oxygen requirement during intravenous fluids.
Persistent hypotension, confusion or falling urine output despite assessed treatment.
Excessive sedation, slowing respiration or difficulty waking after opioid administration.

03Assessment before treatmentTests and checks that guide safe selection.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
A fluid-response assessmentFirst step
Why
Link each infusion decision to observed perfusion and respiratory effects.
Interpretation and limitations
Measure pulse, pressure, urine output and clinical perfusion before and after an intervention, and reassess breathing and congestion at the same time. A rise in urine output with improved circulation and no respiratory deterioration supports benefit. Persistent hypoperfusion, particularly alongside congestion, calls for experienced reassessment rather than repetition of an unexamined bolus.
02
Renal function, electrolytes and glucose
Why
Identify organ dysfunction and modifiers of fluids, medicines and feeding.
Interpretation and limitations
Use baseline and trend information to individualise treatment. Renal impairment alters both fluid tolerance and opioid safety; dehydration or malnutrition also lowers the daily maximum for the selected intravenous paracetamol product. Check potassium, magnesium and phosphate when clinically indicated, especially with nutritional risk, and address abnormalities through the relevant monitored replacement plan.
03
Pain, sedation and respiratory observations
Why
Determine whether analgesia is effective and remains safe.
Interpretation and limitations
Document pain relief together with respiratory rate, alertness and haemodynamics after intravenous opioids and during PCA. A low pain score with increasing sedation is not a successful endpoint. Withhold further opioid delivery and obtain urgent assessment if clinically significant sedation or respiratory depression develops; airway support and reversal treatment may be needed by the responding team.
04
Daily oral and enteral intake review
Why
Choose nutrition from actual delivery and tolerance.
Interpretation and limitations
If oral intake is feasible, introduce food without waiting for lipase to normalise. In moderately severe or severe disease with inadequate oral intake, initiate enteral feeding within 72 hours of presentation. Nasogastric and nasojejunal routes are both usable; do not postpone otherwise suitable nasogastric feeding solely while waiting for jejunal access. Polymeric feed is acceptable, with dietetic adjustment to requirements.

04Treatment approachPreparation, options, escalation and aftercare.

01Worked caseA moderate plan with measured responseFirst stepA constructed 70 kg adult example has early pancreatitis, hypovolaemia and no shock or cardiorenal limitation.

1A 38-year-old man with hypertriglyceridaemia-associated pancreatitis has dry mucosa, haematocrit 47% and urine output 20 mL/hour. He is alert, has blood pressure 106/68 mmHg and normal renal function, without overload, heart failure, cirrhosis, ileus or biliary/renal tract spasm. The team gives lactated Ringer’s 700 mL intravenously over two hours, then 105 mL/hour, with examination during treatment and a planned early reassessment.
2Vomiting prevents oral analgesia. He receives ALTAN paracetamol 1 g/100 mL intravenously over at least 15 minutes, limited to 3 g/day while dehydrated. For continuing severe pain, the trained pain service cautiously selects hameln morphine 1 mg/mL PCA after its safety checks: a 2 mg/2 mL loading infusion over five minutes, then 1 mg/1 mL demands with a ten-minute lockout and no background infusion. Pain, sedation, respiration and pressure are monitored. At the three-hour review, urine output has risen to 45 mL/hour and pain has fallen to 3/10, with clear lungs, normal alertness and a respiratory rate of 16/min.
3At three hours his blood pressure is 118/76 mmHg, urine output is 45 mL/hour and lungs remain clear without oxygen requirement. Pain has fallen from 9/10 to 3/10; he is alert with respiratory rate 16/min. The team continues a reviewed moderate fluid plan rather than increasing the rate because pancreatitis is present. These observed findings support the response in this patient, not a guarantee for others.
4By the next morning vomiting has settled and he tolerates food and oral fluid. The team reduces and stops intravenous fluid as oral intake meets assessed need, reviews withdrawal of PCA and switches from intravenous analgesia when feasible. Intake, respiratory status and renal function remain satisfactory at the next review; the metabolic cause receives its own specialist management plan.

02Fluid prescriptionApply the evidence to the patientUse when choosing early intravenous fluid for an adult with acute pancreatitis.

1For an eligible early adult presentation, the moderate WATERFALL regimen used lactated Ringer’s 1.5 mL/kg/hour, adding 10 mL/kg over two hours only when hypovolaemic. The trial excluded baseline shock or respiratory failure, eGFR below 60 mL/min/1.73 m², significant heart failure, decompensated cirrhosis and fluid overload, among other conditions. Do not transfer that schedule unchanged to those populations.
2Reassess perfusion and overload during treatment and after any bolus, then repeatedly as the illness evolves. The trial used an early safety assessment around three hours and later checkpoints, but clinical deterioration requires review immediately rather than waiting for a study time point. Adjust the rate to observed need and oral intake.
3If overload appears, reduce or stop fluid and obtain an assessment of respiratory and circulatory status. If hypotension or organ dysfunction persists despite initial care, involve critical care and reassess the mechanism. Aggressive routine hydration produced more overload in the trial and did not establish superior clinical outcomes; neither trial arm supplies a universal shock-resuscitation rule.

03Nutrition routeFeed through a usable gastrointestinal tractUse when deciding between oral food, tube feeding and parenteral support.

1Offer oral food when the patient can tolerate it, taking appetite and vomiting into account. A low-fat solid diet can be used without a compulsory clear-fluid sequence. Do not require enzyme normalisation before feeding, and do not keep a patient nil by mouth solely because pancreatitis was diagnosed.
2Where moderately severe or severe disease prevents adequate eating, involve a dietitian and begin enteral nutrition within 72 hours of presentation. A nasogastric route is acceptable when tolerated; consider nasojejunal access for the appropriate anatomical or tolerance problem. Choose the route that can safely deliver nutrition rather than delaying all feeding for an unnecessary procedural preference.
3Assess parenteral nutrition when enteral feeding is contraindicated or fails to provide sufficient nutrition despite adjustment. Bowel obstruction, mesenteric ischaemia, abdominal compartment syndrome or prolonged ileus can change feasibility. Review delivery, glucose, electrolytes and refeeding risk, and revisit the enteral route as the underlying problem improves.

05Regimens, contraindications and interactionsTreatment details and the circumstances that modify them.

Short-term treatment of moderate pain when the intravenous route is justified or oral administration is not possible; an adjunct when severe pain needs additional analgesia.

ALTAN paracetamol 10 mg/mL solution for infusion

For adults over 50 kg: 1 g in 100 mL intravenously over at least 15 minutes, at least four hours between doses and no more than four doses in 24 hours. Maximum 4 g/day only without hepatic risk; maximum 3 g/day with dehydration, chronic malnutrition, chronic alcohol exposure or hepatocellular insufficiency. The dehydrated case uses 1 g every eight hours, maximum 3 g/day. At creatinine clearance 30 mL/min or below, leave at least six hours between doses. For weight over 33 to 50 kg, use 15 mg/kg per dose and no more than 60 mg/kg/day, capped at 3 g/day.

Check weight and total paracetamol from every product; prescribe both milligrams and millilitres. Contraindicated with paracetamol/propacetamol or excipient hypersensitivity and severe hepatocellular insufficiency. Use the lower daily ceiling for the listed risk factors, reassess daily and switch to oral treatment as soon as possible. Review liver disease, renal impairment and interacting medicines: probenecid may require dose reduction, repeated regular dosing can affect warfarin control, and flucloxacillin plus sepsis, renal impairment or malnutrition increases the risk of high-anion-gap acidosis. Stop paracetamol and investigate if that acidosis is suspected. Pregnancy requires the lowest effective dose for the shortest necessary time; breastfeeding is compatible. Account for the infusion’s fluid, sodium and glucose where relevant.

An explicitly selected strong-opioid option for severe pancreatitis pain in a suitable patient who can understand and operate PCA, within a trained and monitored service.

Hameln morphine sulfate 1 mg/mL for intravenous PCA

Trained-service PCA example for an assessed opioid-naive adult: give 2 mg in 2 mL intravenously over five minutes as a loading dose, then 1 mg in 1 mL per patient demand with a ten-minute lockout and no background infusion. The exact product allows a usual loading range of 1–10 mg, maximum 15 mg, over four to five minutes and an initial 1 mg demand with a five- to ten-minute lockout. Use undiluted 1 mg/mL solution. Individualise under the pain service, monitor the early response and review the need daily; use for the shortest necessary period and plan reduction/discontinuation.

Current European guidance advises cautious, individually selected PCA in pancreatitis; evidence is limited and does not establish superiority over other analgesic delivery. Product 5008 is not interchangeable with hameln product 6426, which lists pancreatitis as a contraindication. For 5008, do not use with opioid/excipient allergy, respiratory depression or obstructive airways disease, head injury or raised intracranial pressure, coma, convulsive disorders, ulcerative colitis or ileus risk, biliary/renal tract spasm, acute alcoholism, phaeochromocytoma, GFR below 20 mL/min, severe/acute liver failure or MAOI exposure within two weeks. Reduce doses for older or debilitated patients and noncontraindicated renal/chronic hepatic disease. Pregnancy and breastfeeding use is not recommended. Monitor pain, sedation, respiration, pressure and bowel function; stop delivery and seek urgent help for excessive sedation or respiratory depression. Morphine can provoke sphincter-of-Oddi spasm and aggravate pancreatic/biliary symptoms. Avoid concurrent sedatives unless necessary; if used, minimise doses/duration and intensify monitoring. Explain dependence risk, review the stop plan and taper when continued exposure makes withdrawal a concern.

06Complications, monitoring and follow-upAdverse effects, response and longer-term review.

Give the fluid prescription an explicit reassessment time and safety triggers. Record achieved urine output and perfusion, respiratory findings and oral intake; a planned rate should change when its original indication resolves or signs of harm appear.
During PCA, use the trained service’s observation system to assess pain, sedation, respiration and blood pressure, especially during initiation and dose changes. Only the patient should activate patient-controlled doses; inability to use the device safely requires another monitored analgesic strategy.
Review the cumulative paracetamol dose and the current weight, renal and hepatic risk profile each day. Resolution of dehydration is a clinical reassessment, not permission to overlook malnutrition, alcohol exposure or another reason for the lower maximum.
Record calories and protein actually delivered, vomiting, abdominal tolerance and glucose/electrolyte trends. Plan dietetic follow-up when intake remains poor; a feeding tube in place does not establish that nutritional needs have been met.

07Special situationsVariants, exceptions and circumstances that change the usual approach.

The trial is a defined population

The moderate-fluid evidence is particularly useful for avoiding reflex aggressive hydration in early uncomplicated adults. Patients excluded for shock, established respiratory failure, significant heart disease or impaired baseline kidney function need a separate physiological assessment. A numerical example is useful only when its eligibility and reassessment rules travel with it.

Analgesic selection is formulation-specific

An opioid class recommendation in professional pancreatitis guidance does not override an individual product’s contraindications. The selected PCA formulation has a different licensed method of administration and safety wording from some concentrated morphine injections. Record the exact product and route, and do not borrow a convenient dose or administration time from another SmPC.

A functioning bowel does not need rest

Pancreatitis does not create a universal reason to withhold luminal nutrition. The practical barriers are intolerance, inadequate intake or a specific contraindication. Oral feeding and tube feeding are parts of a reassessed continuum; the transition should follow what the patient can safely receive rather than an arbitrary enzyme threshold.

Persistent symptoms require explanation

Continuing pain, vomiting or failure to eat may reflect a complication, obstruction, ileus, medication effect or another problem. Escalating opioids or changing feed alone can conceal the issue. Re-examine the patient, review the trajectory and investigate a specific concern while maintaining appropriate symptom relief and nutrition.

08Common pitfallsFrequent interpretation and management errors.

01
Applying a fixed aggressive infusion to every pancreatitis admission or using a generic sepsis bolus as its routine default; reassess the actual circulation and the population to which the evidence applies.
02
Treating oliguria with repeated fluid despite new crackles and increasing oxygen need; assess overload, organ injury and the previous response before further volume.
03
Assuming that all morphine injections share the same contraindications or PCA instructions; pancreatitis guidance and the exact selected product must both support the prescription.
04
Leaving a patient without nutrition until pain or lipase has completely normalised, or delaying suitable gastric feeding solely while waiting for jejunal access.

Find your next topic